Dia Dipasupil/Getty Images Entertainment Pfizer’s ( NYSE: PFE ) CEO Albert Bourla has said the drugmaker is testing three new weight loss drugs, one of which will have a different mechanism from currently available GLP-1 agonists. Bourla’s statement was made at a Semafor business event on Monday. He did not reveal the exact mechanism of the third drug, but mentioned the other two would be GLP-1 candidates similar to Novo Nordisk’s ( NVO ) Wegovy, which recently received approval in China .
The chief executive also said Pfizer plans to release data later in 2024 showing progress in development of one of the weight loss therapy candidates, danuglipron. Besides danuglipron, other drug candidates in mid-stage development for obesity include Viking Therapeutics’ ( VKTX ) VK2735, Structure Therapeutics’ ( GPCR ) GSBR-1290, Altimmune’s ( ALT ) pemvidutide, Zealand Pharma’s ( OTCPK:ZLDPF ) petrelintide and Amgen’s ( AMGN ) AMG133, also known as MariTide. The current weight loss blockbusters, Eli Lilly’s ( LLY ) Zepbound and Novo Nordisk’s ( NVO ) Wegovy, are likely to dominate the market even if other drugs are approved, according to analysts speaking during a panel discussion on GLP-1 drugs at the recent Seeking Alpha Investing Summit in New York.
More on Pfizer Pfizer: Seriously Undervalued At Peak Pessimism Pfizer Stock: The Reversal Should Keep Going Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Lilly, Novo Nordisk to dominate weight l.